442 related articles for article (PubMed ID: 28457968)
1. 17beta-hydroxysteroid dehydrogenase type 5 is negatively correlated to apoptosis inhibitor GRP78 and tumor-secreted protein PGK1, and modulates breast cancer cell viability and proliferation.
Xu D; Aka JA; Wang R; Lin SX
J Steroid Biochem Mol Biol; 2017 Jul; 171():270-280. PubMed ID: 28457968
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of 17beta-hydroxysteroid dehydrogenase type 7 modulates breast cancer protein profile and enhances apoptosis by down-regulating GRP78.
Wang XQ; Aka JA; Li T; Xu D; Doillon CJ; Lin SX
J Steroid Biochem Mol Biol; 2017 Sep; 172():188-197. PubMed ID: 28645527
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
[TBL] [Abstract][Full Text] [Related]
4. 17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.
Aka JA; Zerradi M; Houle F; Huot J; Lin SX
Breast Cancer Res; 2012 Jun; 14(3):R92. PubMed ID: 22691413
[TBL] [Abstract][Full Text] [Related]
5. Structures of complexes of type 5 17β-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor binding.
Amano Y; Yamaguchi T; Niimi T; Sakashita H
Acta Crystallogr D Biol Crystallogr; 2015 Apr; 71(Pt 4):918-27. PubMed ID: 25849402
[TBL] [Abstract][Full Text] [Related]
6. Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
Aka JA; Calvo EL; Lin SX
Mol Cell Endocrinol; 2017 Jan; 439():175-186. PubMed ID: 27544780
[TBL] [Abstract][Full Text] [Related]
7. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
[TBL] [Abstract][Full Text] [Related]
10. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
Zhang D; Tai LK; Wong LL; Chiu LL; Sethi SK; Koay ES
Mol Cell Proteomics; 2005 Nov; 4(11):1686-96. PubMed ID: 16048908
[TBL] [Abstract][Full Text] [Related]
11. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Jia Y; Domenico J; Swasey C; Wang M; Gelfand EW; Lucas JJ
PLoS One; 2014; 9(5):e97448. PubMed ID: 24848372
[TBL] [Abstract][Full Text] [Related]
12. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
[TBL] [Abstract][Full Text] [Related]
13. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
14. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
15. 11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.
Yoda T; Kikuchi K; Miki Y; Onodera Y; Hata S; Takagi K; Nakamura Y; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H; McNamara KM
Mol Cell Endocrinol; 2015 Sep; 413():236-47. PubMed ID: 26170067
[TBL] [Abstract][Full Text] [Related]
16. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
[TBL] [Abstract][Full Text] [Related]
17. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
[TBL] [Abstract][Full Text] [Related]
18. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
19. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
20. Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Plourde M; Ferland A; Soucy P; Hamdi Y; Tranchant M; Durocher F; Sinilnikova O; Luu The V; ; Simard J
J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):134-53. PubMed ID: 19460435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]